Compare Quest Diagnostics Inc (DGX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Mesoblast Limited — how do they compare? Quest Diagnostics Inc trades at $236.29 (market cap $26.24B), while Mesoblast Limited trades at $15.7 (market cap $2.20B). The key difference: Quest Diagnostics Inc is far larger — about 11.9× Mesoblast Limited's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| DGX | MESO | |
|---|---|---|
Market Cap | $26.24B | $2.20B |
Sector | Health | Technology |
52-Week High | $238.50 | $20.96 |
52-Week Low | $173.49 | $12.88 |
Enterprise Value | $32.00B | $2.20B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $236.04, down 0.61% on the day, as the stock consolidates near recent highs following strong Q2 2026 earnings. The company has delivered three consecutive quarterly earnings beats, with Q2 EPS of $3.12 exceeding expectations by 10.6%. Revenue growth accelerated to 10.2% year-over-year, supported by strong testing demand and strategic partnerships. Technical indicators show a bullish trend with the stock trading near pivot point resistance at $238.
The outlook remains positive with raised 2026 guidance and consistent dividend payments, though valuation multiples appear full at 25.2x P/E. Key risks include margin pressure from lower-margin contracts and rising project costs. Analyst consensus leans bullish with a $249.50 price target representing 5.7% upside potential from current levels.
MESO trades at $16.78, down 0.83% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong revenue growth with Ryoncil generating $115 million in its first full year, though it remains unprofitable with a -144.33% net income margin. Recent developments include achieving Phase 3 trial targets for chronic back pain and securing a $50 million non-dilutive facility.
MESO presents a high-risk, high-reward opportunity with significant commercial traction but persistent losses. The bullish analyst consensus and recent regulatory progress support upside potential, though profitability concerns and high P/S ratio of 30.52 warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
